Elanco Animal Health Inc (ELAT)
NYSE: ELAT
· Real-Time Price · USD
21.32
0.22 (1.04%)
At close: Jan 31, 2023, 10:00 PM
Elanco Animal Health Inc Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|
| Cattle Revenue | 1.01B | 949M | 944M | 82M | 80.2M |
| Cattle Revenue Growth | +6.11% | +0.53% | +1051.22% | +2.24% | n/a |
| Contract Manufacturing Revenue | 46M | 42M | 54M | 2.33B | n/a |
| Contract Manufacturing Revenue Growth | +9.52% | -22.22% | -97.68% | n/a | n/a |
| Farm Animal Revenue | 2.25B | 2.27B | 2.22B | 2.35B | n/a |
| Farm Animal Revenue Growth | -0.92% | +2.34% | -5.61% | n/a | n/a |
| Pet Health Revenue | 2.14B | 2.1B | 2.14B | n/a | n/a |
| Pet Health Revenue Growth | +1.85% | -1.59% | n/a | n/a | n/a |
| Poultry Revenue | 796M | 765M | 716M | n/a | n/a |
| Poultry Revenue Growth | +4.05% | +6.84% | n/a | n/a | n/a |
| Swine Revenue | 366M | 382M | 384M | n/a | n/a |
| Swine Revenue Growth | -4.19% | -0.52% | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 2.4B | 2.43B | 2.45B | 2.64B | 1.8B | 1.55B | 1.58B |
| Non-Us Revenue Growth | -1.27% | -0.49% | -7.38% | +46.91% | +16.26% | -2.36% | n/a |
| United States Revenue | 2.04B | 1.98B | 1.97B | 2.12B | 1.48B | 1.52B | 1.48B |
| United States Revenue Growth | +2.67% | +0.92% | -7.49% | +43.94% | -3.22% | +2.80% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 341M | 321M | 323M | 313M | 353M | 327M | 303M | 298M | 343M | 320M | 329M | 342M | 385M | 348M | 985.1M | 277.7M | 211.8M | 233.6M | 237.3M | 243M | 250.2M | 230.1M | 235.2M | 227.7M | 240.5M | 229.2M | 257M | 246.3M |
| Selling, General, and Administrative Revenue Growth | +6.23% | -0.62% | +3.19% | -11.33% | +7.95% | +7.92% | +1.68% | -13.12% | +7.19% | -2.74% | -3.80% | -11.17% | +10.63% | -64.67% | +254.74% | +31.11% | -9.33% | -1.56% | -2.35% | -2.88% | +8.74% | -2.17% | +3.29% | -5.32% | +4.93% | -10.82% | +4.34% | n/a |
| Research and Development Revenue | 94M | 96M | 87M | 86M | 81M | 81M | 80M | 78M | 82M | 81M | 92M | 94M | 94M | 89M | 112.7M | 88.1M | 59.4M | 66.8M | 67.3M | 69.9M | 68.8M | 64.1M | 61.1M | 58.9M | 61.4M | 65.2M | 62M | 61.9M |
| Research and Development Revenue Growth | -2.08% | +10.34% | +1.16% | +6.17% | 0.00% | +1.25% | +2.56% | -4.88% | +1.23% | -11.96% | -2.13% | 0.00% | +5.62% | -21.03% | +27.92% | +48.32% | -11.08% | -0.74% | -3.72% | +1.60% | +7.33% | +4.91% | +3.74% | -4.07% | -5.83% | +5.16% | +0.16% | n/a |